Pulse Biosciences, Inc. (NASDAQ:PLSE) Short Interest Update
Pulse Biosciences (NASDAQ:PLSE) experienced a significant drop in short interest in June, with a decrease of 14.4% compared to May. Currently, 14.9% of the company's shares are sold short. The days-to-cover ratio is 11.0 days based on the average daily trading volume. The company's stock performance has shown a range between $3.78 and $14.96 over the past year. CEO Burke Thomas Barrett recently purchased 10,000 shares of the stock. Institutional investors and hedge funds hold approximately 76.95% of the stock.
Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) saw a large drop in short interest in June. As of June 15th, there was short interest totalling 2,430,000 shares, a drop of 14.4% from the May 31st total of 2,840,000 shares. Based on an average daily volume of 220,500 shares, the short-interest ratio is currently 11.0 days. Currently, 14.9% of the shares of the company are sold short.
Get Pulse Biosciences alerts:
Pulse Biosciences Stock Performance
Shares of NASDAQ PLSE opened at $11.19 on Friday. Pulse Biosciences has a 12 month low of $3.78 and a 12 month high of $14.96. The company has a 50 day simple moving average of $10.06 and a two-hundred day simple moving average of $9.55.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Thursday.
Read Our Latest Report on Pulse Biosciences
Insider Buying and Selling
In related news, CEO Burke Thomas Barrett bought 10,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was bought at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the purchase, the chief executive officer now directly owns 10,000 shares of the company's stock, valued at $85,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 71.50% of the stock is owned by company insiders.
Hedge Funds Weigh In On Pulse Biosciences
Several large investors have recently made changes to their positions in PLSE. BNP Paribas Financial Markets lifted its stake in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock valued at $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $88,000. Cetera Advisors LLC acquired a new position in shares of Pulse Biosciences in the 1st quarter valued at $109,000. PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences in the 4th quarter valued at $242,000. Finally, Inspire Investing LLC lifted its stake in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock valued at $360,000 after purchasing an additional 10,039 shares during the period. 76.95% of the stock is currently owned by institutional investors and hedge funds.
About Pulse Biosciences
(Get Free Report)Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Recommended Stories
- Five stocks we like better than Pulse Biosciences
- What is a buyback in stocks? A comprehensive guide for investors
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Stock Market Sectors: What Are They and How Many Are There?
- What's Behind Walgreens Stock Plunge: What Investors Can Do Next
- What Is WallStreetBets and What Stocks Are They Targeting?
- MarketBeat Week in Review – 6/24 - 6/28
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Where AI is REALLY Going Next (From InvestorPlace) (Ad)
Should you invest $1,000 in Pulse Biosciences right now?
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
